Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/31948
Type
ArticleCopyright
Restricted access
Embargo date
2050-01-01
Collections
- INI - Artigos de Periódicos [3488]
Metadata
Show full item record
DYSLIPIDEMIA IN A COHORT OF HIV-INFECTED LATIN AMERICAN CHILDREN RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Author
Affilliation
Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA./ Office of HIV/AIDS, The United States Agency for International Development, Washington, USA.
Westat. Rockville, MD, USA.
Westat. Rockville, MD, USA.
Clinica de Inmunodeficiencias/Depto. Infectología; Hospital Infantil de Mexico Federico Gomez, Mexico
Clinica de Inmunodeficiencias/Depto. Infectología; Hospital Infantil de Mexico Federico Gomez, Mexico
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil.
School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Instituto da Crianca – HCFM Universidade de Sao Paulo, Sao Paulo, Brazil.
Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA.
Westat. Rockville, MD, USA.
Westat. Rockville, MD, USA.
Clinica de Inmunodeficiencias/Depto. Infectología; Hospital Infantil de Mexico Federico Gomez, Mexico
Clinica de Inmunodeficiencias/Depto. Infectología; Hospital Infantil de Mexico Federico Gomez, Mexico
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil.
School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Instituto da Crianca – HCFM Universidade de Sao Paulo, Sao Paulo, Brazil.
Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA.
Abstract
In order to describe the prevalence of hypercholesterolemia and hypertriglyceridemia in a cohort of HIV-infected children and adolescents in Latin America and to determine associations with highly active antiretroviral therapy (HAART), we performed this cross-sectional analysis within the NICHD International Site Development Initiative pediatric cohort study. Eligible children had to be at least 2 years of age and be on HAART. Among the 477 eligible HIV-infected youth, 98 (20.5%) had hypercholesterolemia and 140 (29.4%) had hypertriglyceridemia. In multivariable analyses, children receiving protease inhibitor (PI)-containing HAART were at increased risk for hypercholesterolemia [adjusted odds ratio (AOR) = 2.7, 95% confidence interval (CI) 1.3-5.6] and hypertriglyceridemia (AOR = 3.5, 95% CI 1.9-6.4) compared with children receiving non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing HAART. In conclusion, HIV-infected youth receiving PI-containing HAART in this Latin American cohort were at increased risk for hypercholesterolemia and hypertriglyceridemia compared with those receiving NNRTI-containing HAART.
Share